GlobeNewsWire
05 Jun 2026, 11:32 UTC · 2h ago
Top 1 mover · tap to explore
Story key points
2 claims · impact-rated
Clearmind Medicine will present new clinical data from its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder during a webinar on June 10, 2026. — Early-stage clinical data updates for lead drug candidates are primary catalysts for biotech stock price volatility.
+0.40Researchers from Yale and Johns Hopkins will present the early findings of the CMND-100 trial. — Validation from prestigious academic institutions increases the credibility of the clinical results.
+0.20Ticker attribution
Model heads
The company is hosting a webinar to present clinical trial data and insights from prestigious institutions, which is generally a positive catalyst for a clinical-stage biotech.
Continue reading
6 related stories
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
16h ago
